Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

Heart failure (HF) in patients at risk is often overlooked, and when detected, there is a lack of early and effective preventive interventions. The WE-CARE-HF-CMR study, conducted in large cities/metropol areas in Germany ( \> 1.000.000 inhabitants), aims to close this gap by evaluating the feasibility of a mobile, telemedicinemonitored HF-screening approach combining cardiac magnetic resonance imaging (CMR), quality of life assessment and laboratory tests as key elements in asymptomatic patients at risk. WE-CARE-HF-CMR will provide a proposal for a comprehensive, contemporary screening approach for patients at risk to develop HF tailored to the needs of the target population. This will provide important new information on the prevalence of asymptomatic HF in at-risk patients in urban versus rural areas. The results of the study will be compared with the results from the "HERZCheck'' trial, which provides data from approximately 4,500 participants in rural areas in Germany and has already been completed (NCT05122793).

NCT Number	NCT07185100
Lead Sponsor	German Heart Institute Collaborators: AstraZeneca, Philips Healthcare, Deutsches Herzzentrum der Charité, Berlin, German Heart Center Foundation, Nationale Herzallianz (NHA), Deutsche Herzstiftung
Conditions	Heart Failure With Preserved Ejection Fraction (HFPEF), Renal Dysfunction, Stage B Heart Failure
Enrollment	600 participants
Start Date	2025-09-13
Primary Completion	2026-12-31 (estimated)
Study Completion	2036-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-01